IRLAB Therapeutics AB (publ) (IRLAB_A) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to this live broadcasted Q1 presentation by research company IRLAB Therapeutics. Presenting today is CEO Kristina Torfgaard, Executive Vice President Research and Development Niklas Waters and CFO Viktor Sivic. After the presentation there will be a Q&A session with equity analysts and viewers can ask their questions in the live chat. Hello and welcome, Kristina Torfgård. Hello and thank you very much. So please go ahead with your presentation and I'll be back for the Q&A. Sure, thanks. So first of all, on behalf of iLab, I would like to welcome everyone to today's webcast where we are going to present the Q1 report. And if we start with the slides, please. And the next one. is our disclaimers, and then we have the agenda. Next one. So I will start and take you through the news of the period. After that, I will hand over to Nicholas Waters to take you through the R&D update. And this will be followed by a financial update by Victor Sievert. And I will then make a concluding words, and then we will start off the Q&A session. So the next slide, please. I would like to remind everyone and start with this slide. And this is really the basis here for our research. Parkinson's disease is a severe and devastating disease. The second largest of the neurological diseases. And as you can see here on this slide, we can see that there are a number of different symptoms and complications that those individuals that are living with Parkinson's experience. What we have is that we have five first in class candidates. And if we move on to another click there, we have five candidates where they all have a unique, can you click one more? Yes, thank. So we have five candidates in development where we have all are first in class with a unique mechanism of action. Three of them ar...